TY - CHAP
T1 - Radiobismuth for Therapy
AU - Brechbiel, Martin W.
AU - Dadachova, Ekaterina
PY - 2010/11/15
Y1 - 2010/11/15
KW - 213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage
KW - Cancer treatment, and surgery - external beam radiation therapy and chemotherapy
KW - Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies
KW - Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody
KW - Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery
KW - Radiobismuth for therapy
KW - Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies
KW - Targeted a-therapy versus targeted b-therapy
KW - Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors
KW - Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies
UR - http://www.scopus.com/inward/record.url?scp=79960539306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960539306&partnerID=8YFLogxK
U2 - 10.1002/9780470975503.ch13
DO - 10.1002/9780470975503.ch13
M3 - Chapter
AN - SCOPUS:79960539306
SN - 9780470713907
SP - 311
EP - 329
BT - Biological Chemistry of Arsenic, Antimony and Bismuth
PB - John Wiley and Sons
ER -